Akeega (niraparib and abiraterone acetate) — Medica
metastatic castration-resistant prostate cancer with BRCA mutation
Initial criteria
- age ≥ 18 years
- diagnosis of metastatic castration-resistant prostate cancer
- presence of BReast CAncer (BRCA) mutation
- used in combination with prednisone
- ONE of the following: (i) used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR (ii) patient has had a bilateral orchiectomy
Approval duration
1 year